01 febrero 2014

JOURNAL OF ENDOVASCULAR THERAPY. Long-Term Outcomes of Endovascular Therapy for Aortoiliac Bifurcation Lesions in the Real-AI Registry

Hideaki Aihara, MD1⇑ Yoshimitsu Soga, MD1 Osamu Iida, MD2 Kenji Suzuki, MD3 Junichi Tazaki, MD4 Yoshiaki Shintani, MD5 Yusuke Miyashita, MD on behalf of the REAL-AI Registry Investigators

Purpose: To report long-term outcomes of endovascular therapy (EVT) for aortoiliac bifurcation lesions.

01 febrero 2014

JOURNAL OF ENDOVASCULAR THERAPY. Nitinol Self-Expanding Stents vs. Balloon Angioplasty for Very Long Femoropopliteal Lesions

Ehrin J. Armstrong, MD, MSc1 Haseeb Saeed, MD2 Bejan Alvandi, BS2 Satinder Singh, MD2 Gagan D. Singh, MD2 Khung Keong Yeo, MBBS2 David Anderson, BA2 Gregory G. Westin, BA2 David L. Dawson, MD3 William C. Pevec, MD3 John R. Laird, MD2⇑

Purpose: To compare the patency rates and clinical outcomes of balloon angioplasty vs. nitinol stent placement for patients with short (≤150 mm) as compared to long (>150 mm) femoropopliteal (FP) occlusive lesions.

01 febrero 2014

JOURNAL OF ENDOVASCULAR THERAPY. Early Recoil After Balloon Angioplasty of Tibial Artery Obstructions in Patients With Critical Limb Ischemia

Frederic Baumann, MD1,2 Jacqueline Fust3 Rolf Peter Engelberger, MD1 Ulrike Hügel, MD1 Do-Dai Do, MD1 Torsten Willenberg, MD1 Iris Baumgartner, MD1 Nicolas Diehm, MD1⇑

Purpose To assess the extent of early recoil in patients with critical limb ischemia (CLI) undergoing conventional tibial balloon angioplasty.

01 febrero 2014

JOURNAL OF ENDOVASCULAR THERAPY. Photoablation Using the Turbo-Booster and Excimer Laser for In-Stent Restenosis Treatment: Twelve-Month Results From the PATENT Study

Andrej Schmidt, MD1⇑ Thomas Zeller, MD2 Horst Sievert, MD3 Hans Krankenberg, MD4 Giovanni Torsello, MD5 Matthew A. Stark, PhD6 Dierk Scheinert, MD1

Purpose: To evaluate the performance of the Turbo Elite laser catheter in combination with the Turbo-Booster guiding catheter for the treatment of femoropopliteal in-stent restenosis (ISR).

01 febrero 2014

JOURNAL OF ENDOVASCULAR THERAPY. Revascularization of Lower Extremity Chronic Total Occlusions With a Novel Intraluminal Recanalization Device: Results of the ReOpen Study

Marc Bosiers, MD1⇑ Juan Diaz-Cartelle, MD2 Dierk Scheinert, MD3 Patrick Peeters, MD4 Keith D. Dawkins, MD2

Purpose To report outcomes of a multicenter, nonrandomized study evaluating the safety and effectiveness of a guidewire-mounted mechanical recanalization device with a rotating distal tip (TruePath) in facilitating the crossing of infrainguinal chronic total occlusions (CTOs).

01 febrero 2014

JOURNAL OF ENDOVASCULAR THERAPY. Blunt Microdissection for Endovascular Treatment of Infrainguinal Chronic Total Occlusions

Subhash Banerjee, MD1,2⇑ Omar Hadidi, MD2 Atif Mohammad, MD2 Ali Alsamarah, MD2 Rahul Thomas, MD2 Karan Sarode, MA1,2 Puja Garg, PhD2 Mirza S. Baig, MD1,2 Emmanouil S. Brilakis, MD, PhD1,2

Purpose: To present a systematic safety evaluation of the CrossBoss blunt microdissection catheter for crossing peripheral chronic total occlusions (CTOs).

01 febrero 2014

JOURNAL OF ENDOVASCULAR THERAPY. Comparison of Collagen-Based Vascular Closure Devices in Patients With vs. Without Severe Peripheral Artery Disease

Kaffer Kara, MD1⇑ Philip Kahlert, MD1 Amir A. Mahabadi, MD1 Björn Plicht, MD1 Alexander Y. Lind, MD1 Detlev Longwitz, MD2 Matthias Bollow, MD2 Raimund Erbel, MD1

Purpose: To compare complication rates of a collagen-based vascular closure device (VCD) in patients with vs. without significant peripheral artery disease (PAD).

01 febrero 2014

JOURNAL OF ENDOVASCULAR THERAPY. One-Year Outcomes Following Repair of Thoracoabdominal Aneurysms With the Multilayer Flow Modulator: Report From the STRATO Trial

Claude D. Vaislic, MD1⇑ Jean Noël Fabiani, MD, PhD2 Sidney Chocron, MD, PhD3 Jacques Robin, MD4 Victor S. Costache, MD5 Jean-Pierre Villemot, MD, PhD6 Jean Marc Alsac, MD2 Pascal N. Leprince, MD, PhD7 Thierry Unterseeh, MD8 Eric Portocarrero, MD6 Yves Glock, MD, PhD9 Hervé Rousseau, MD, PhD on behalf of the STRATO Investigators Group

Purpose: To evaluate endovascular repair of type II and III thoracoabdominal aortic aneurysms (TAAA) using the Multilayer Flow Modulator (MFM) in patients with contraindications for open surgery and fenestrated stent-grafts.

01 febrero 2014

JOURNAL OF ENDOVASCULAR THERAPY. When Not to Implant the Multilayer Flow Modulator: Lessons Learned From Application Outside the Indications for Use in Patients With Thoracoabdominal Pathologies

Sherif Sultan, MCh, MD, FRCS, EBQS/Vasc1,2 Niamh Hynes, MD, MRCS2 Mohamed Sultan on behalf of the MFM Collaborators

Purpose: To scrutinize registry data on thoracoabdominal repairs performed using the Multilayer Flow Modulator (MFM) outside the indications for use (IFU) and analyze the adverse outcomes.

01 marzo 2014

RADIOLOGY. Inferior Mesenteric Arterial Type II Endoleaks after Endovascular Repair of Abdominal Aortic Aneurysm: Are They Predictable?

Oliver Güntner, MD, Florian Zeman, MMath, Walter A. Wohlgemuth, MD, Peter Heiss, MD, Ernst Michael Jung, MD, Philipp Wiggermann, MD, Karin Pfister, MD, Christian Stroszczynski, MD, René Müller-Wille, MD

Endovascular aortic aneurysm repair (EVAR) is widely accepted as a less-invasive alternative to traditional open surgery in patients with an infrarenal abdominal aortic aneurysm. However, type II endoleaks continue to be the most common complications observed after EVAR, occurring in 19%–23% of patients (1,2). Type-II endoleaks are caused by retrograde collateral blood flow into the aneurysm sac from patent aortic side branches such as the inferior mesenteric artery (IMA), lumbar arteries, or median sacral artery (3). Type II endoleaks can be classified as simple or complex. Simple endoleaks have only one artery in communication with the aneurysm sac, whereas complex endoleaks have multiple communicating arteries (3). Persistent flow in the IMA is responsible for 45%–85% of all type II endoleaks after EVAR (4,5). Baum and colleagues (6) demonstrated that retrograde blood flow in the IMA transmits nearly systemic pressures to the aneurysm sac. Persistent pressurization of the aneurysm sac is significantly associated with aneurysm sac growth, repeated secondary intervention, conversion to open repair, and even aneurysm rupture (2,7,8).

01 febrero 2014

RADIOLOGY. Cellular Mechanisms of Aneurysm Occlusion after Treatment with a Flow Diverter

Ramanathan Kadirvel, PhD, Yong-Hong Ding, MD, Daying Dai, MD, Issa Rezek, MD, Debra A. Lewis, PhD, David F. Kallmes, MD

Flow diverters provide a noninvasive way of treating aneurysms that are otherwise difficult to treat with other endovascular techniques. Even though flow diverters are widely applied, their exact mechanism of action remains unknown. Notwithstanding the term flow diverter, which implies that the primary mode of action is diversion of flow from the aneurysm (1–4), it remains unclear whether change in intraaneurysmal flow, tissue growth across the neck, or both processes are dominant predictors of long-term occlusion. Ongoing uncertainty regarding the exact healing mechanism associated with flow diverters has myriad consequences, including but not limited to impeding our ability to develop next-generation devices. The objective of our study was to characterize the progression of healing across aneurysm necks following treatment with a flow diverter in a rabbit model.

03 diciembre 2013

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Peripheral Artery Disease. Preoperative Statins and Limb Salvage After Lower Extremity Revascularization in the Medicare Population

Todd R. Vogel, MD, MPH, Viktor Y. Dombrovskiy, MD, PhD, MPH, Edgar Luis Galiñanes, MD and Robin L. Kruse, PhD

Background: Statins stabilize atherosclerotic plaque, decrease mortality after surgical procedures, and are linked to anti-inflammatory effects. The objective of this study was to evaluate preoperative administration of statins and longitudinal limb salvage after lower extremity endovascular revascularization and lower extremity open surgery.

12 noviembre 2013

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. New Techniques Adventitial Nab-Rapamycin Injection Reduces Porcine Femoral Artery Luminal Stenosis Induced by Balloon Angioplasty via Inhibition of Medial Proliferation and Adventitial Inflammation

Warren J. Gasper, MD, Cynthia A. Jimenez, MD, Joy Walker, MD, Michael S. Conte, MD, Kirk Seward, PhD and Christopher D. Owens, MD

Background: Endovascular interventions on peripheral arteries are limited by high rates of restenosis. Our hypothesis was that adventitial injection of rapamycin nanoparticles would be safe and reduce luminal stenosis in a porcine femoral artery balloon angioplasty model.

19 septiembre 2014

CIRCULATION. Vascular Medicine. Clinical Trials in Peripheral Vascular Disease. Pipeline and Trial Designs: An Evaluation of the ClinicalTrials.gov Database

Sumeet Subherwal, MD, MBA; Manesh R. Patel, MD; Karen Chiswell, PhD; Beth A. Tidemann-Miller, PhD; W. Schuyler Jones, MD; Michael S. Conte, MD; Christopher J. White, MD; Deepak L. Bhatt, MD, MPH; John R. Laird, MD; William R. Hiatt, MD; Asba Tasneem, PhD; Robert M. Califf, MD

Background: Tremendous advances have occurred in therapies for peripheral vascular disease (PVD); until recently, however, it has not been possible to examine the entire clinical trial portfolio of studies for the treatment of PVD (both arterial and venous disease).

01 septiembre 2014

AMERICAN HEART JOURNAL. Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention

Lisa Tully, MD, Eugenia Gianos, MD, Anish Vani, BS, Yu Guo, MA, Revathi Balakrishnan, MD, Arthur Schwartzbard, MD, James Slater, MD, Richard Stein, MD, James Underberg, MD, Howard Weintraub, MD, Edward Fisher, MD, Jeffrey S. Berger, MD, MS

Background: The American Heart Association recommends targeting 7 cardiovascular (CV) health metrics to reduce morbidity and mortality. Control of these targets in patients undergoing CV intervention is uncertain.